摘要
胃肠间质瘤(GIST)发生的关键因素是c-KIT原癌基因和血小板衍生生长因子受体α(PDGFRα)的突变。GIST确诊要根据病理学和免疫组化结果。手术切除仍然是局限性GIST的主要治疗手段。酪氨酸激酶抑制剂伊马替尼是治疗转移和复发GIST的一线药物。但随着伊马替尼治疗时间的延长,绝大多数GIST患者会对伊马替尼产生耐药性。而多靶点酪氨酸激酶抑制剂的问世已经成为耐药和不能耐受伊马替尼治疗的GIST患者的二线用药。
The key events in GIST pathogenesis is the mutation of the c-kit proto-oncogene and the platelet derived growth factor receptor genes.Final diagnosis depends on the pathology and immunohistochemistry.Surgery is the mainstay treatment of localized resectable GIST.Tyrosine kinase inhibitor,imatinib is the standard of care for metastatic disease.However,as the period of treatment extends,a majority of patients with metastatic disease ultimately cease to respond to imatinib.Sunitinib has become the second-line regimen of GIST patients,whose diseases have progressed on imatinib or been unable to tolerate the treatment with imatinib.
出处
《医学综述》
2010年第10期1488-1491,共4页
Medical Recapitulate
关键词
胃肠间质瘤
诊断
分子靶向治疗
C-KIT
酪氨酸激酶抑制剂
Gastrointestinal stromal tumors
Diagnosis
Molecular targeted therapy
c-KIT
Tyrosine kinase inhibitor
